X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.61 USD
-0.03 (-4.86%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $0.64 +0.04 (5.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
X4 Pharmaceuticals, Inc. [XFOR]
Reports for Purchase
Showing records 41 - 60 ( 95 total )
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Completed for Phase 3 WHIM Study & More 4Q2021 Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - Data-Rich 2H21 & 2022 With Expected Valuation Upside
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Milestones Achieved; Multiple Catalysts in 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Clinical Update at EHA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Promising Early Data For Mavorixafor in Waldenstrom, Raising PT to $27
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging First Look at Mavorixafor for WM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EHA Update - Mavorixafor + Ibrutinib Could Be Synergistic in Waldenstrom
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Peek at Data From WM Study Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- WM Data at EHA in June, and SCN Data Expected by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update - Data Readouts in WM and SCN Still Expected in 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Catalysts Remain On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New CMO, Diego Cadavid, MD is Another Solid Addition to The X4 Team
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z